AIM:This study aims to investigate the sustained and stable drug release profile of the injectable hydrogel lidocaine(LDC)/betamethasone sodium phosphate hydrogel(BetP-Gel)and its effect on analgesic duration in a mouse model of acute incisional pain.METHODS:The drug-loaded hydrogel LDC/BetP-Gel was prepared through a sim-ple mixing process.Its physicochemical properties were characterized using electron microscopy,X-ray diffraction,Fouri-er-transform infrared spectroscopy,and rheological testing.In vivo gelation and injectability were evaluated through posi-tron emission tomography/computed tomography(PET-CT)imaging and pressure variation measurements.The in vitro drug release rate was determined using a direct release method,while the degradation rate was assessed using the residual weight method.A total of thirty BALB/c mice were randomly assigned to five groups:blank group,model group,4%LDC group,BetP-Gel group,and 4%LDC/BetP-Gel group.Pain behavior was assessed using the Up-Down method and Harg-reave's test.Biocompatibility was evaluated through HE staining,and the expression levels of inflammatory cytokines were measured via enzyme-linked immunosorbent assay(ELISA).RESULTS:The LDC/BetP-Gel hydrogel demonstrated ex-cellent drug encapsulation and sustained release properties.Behavioral assessments indicated that the LDC/BetP-Gel group exhibited significantly higher pain thresholds compared to the model group(P＜0.05),suggesting improved postop-erative pain relief.Furthermore,the LDC/BetP-Gel group showed a markedly prolonged analgesic effect compared to the LDC group(P＜0.05).HE staining confirmed the biocompatibility of the hydrogel.ELISA results revealed a significant re-duction in inflammatory cytokine levels in the LDC/BetP-Gel group 24 hours post-surgery(P＜0.05).CONCLUSION:The injectable hydrogel LDC/BetP-Gel possesses a dense and stable structure that enables effective drug loading and sus-tained release.Its ability to prolong anti-inflammatory and analgesic effects has been validated in a mouse model of acute incisional pain.

Objective To observe the efficacy of Venovo venous stent for treating post-thrombotic syndrome(PTS)after lower extremity deep venous thrombosis(DVT).Methods A total of 61 patients with PTS after lower extremioty DVT who underwent iliac vein stent implantation were retrospectively enrolled,including 33 cases underwent Venovo stent(Venovo stent group)and 28 cases underwent conventional stent implantation(conventional stent group).The technical success rates and perioperative complications,Villalta score and venous clinical severity score(VCSS)before and 6 and 12 months after treatment,as well as the primary stent patency were compared within and between groups.Results The technical success rate was 100%in both groups,and no significant difference of the incidence of perioperative complications was found between groups(P=0.187).There was no significant difference of Villalta score nor VCSS between groups before treatment(both P＞0.05),while significant decrease of Villalta score was noticed before and 6 or 12 months after treatment within both groups(all P＜0.05).No significant difference of Villalta score nor VCSS was found 6 months after treatment between groups(both P＞0.05),while significant difference of Villalta score and VCSS were observed in Venovo stent group compared with those in conventional stent group 12 months after treatment(both P＜0.05).No significant difference of primary stent patency rate was found between groups 6 and 12 months after treatment(both P＞0.05).Conclusion Venovo venous stent could be used to effectively treat PTS after lower extremity DVT.

Objective To observe the efficacy of Venovo venous stent for treating post-thrombotic syndrome(PTS)after lower extremity deep venous thrombosis(DVT).Methods A total of 61 patients with PTS after lower extremioty DVT who underwent iliac vein stent implantation were retrospectively enrolled,including 33 cases underwent Venovo stent(Venovo stent group)and 28 cases underwent conventional stent implantation(conventional stent group).The technical success rates and perioperative complications,Villalta score and venous clinical severity score(VCSS)before and 6 and 12 months after treatment,as well as the primary stent patency were compared within and between groups.Results The technical success rate was 100%in both groups,and no significant difference of the incidence of perioperative complications was found between groups(P=0.187).There was no significant difference of Villalta score nor VCSS between groups before treatment(both P＞0.05),while significant decrease of Villalta score was noticed before and 6 or 12 months after treatment within both groups(all P＜0.05).No significant difference of Villalta score nor VCSS was found 6 months after treatment between groups(both P＞0.05),while significant difference of Villalta score and VCSS were observed in Venovo stent group compared with those in conventional stent group 12 months after treatment(both P＜0.05).No significant difference of primary stent patency rate was found between groups 6 and 12 months after treatment(both P＞0.05).Conclusion Venovo venous stent could be used to effectively treat PTS after lower extremity DVT.

AIM:This study aims to investigate the sustained and stable drug release profile of the injectable hydrogel lidocaine(LDC)/betamethasone sodium phosphate hydrogel(BetP-Gel)and its effect on analgesic duration in a mouse model of acute incisional pain.METHODS:The drug-loaded hydrogel LDC/BetP-Gel was prepared through a sim-ple mixing process.Its physicochemical properties were characterized using electron microscopy,X-ray diffraction,Fouri-er-transform infrared spectroscopy,and rheological testing.In vivo gelation and injectability were evaluated through posi-tron emission tomography/computed tomography(PET-CT)imaging and pressure variation measurements.The in vitro drug release rate was determined using a direct release method,while the degradation rate was assessed using the residual weight method.A total of thirty BALB/c mice were randomly assigned to five groups:blank group,model group,4%LDC group,BetP-Gel group,and 4%LDC/BetP-Gel group.Pain behavior was assessed using the Up-Down method and Harg-reave's test.Biocompatibility was evaluated through HE staining,and the expression levels of inflammatory cytokines were measured via enzyme-linked immunosorbent assay(ELISA).RESULTS:The LDC/BetP-Gel hydrogel demonstrated ex-cellent drug encapsulation and sustained release properties.Behavioral assessments indicated that the LDC/BetP-Gel group exhibited significantly higher pain thresholds compared to the model group(P＜0.05),suggesting improved postop-erative pain relief.Furthermore,the LDC/BetP-Gel group showed a markedly prolonged analgesic effect compared to the LDC group(P＜0.05).HE staining confirmed the biocompatibility of the hydrogel.ELISA results revealed a significant re-duction in inflammatory cytokine levels in the LDC/BetP-Gel group 24 hours post-surgery(P＜0.05).CONCLUSION:The injectable hydrogel LDC/BetP-Gel possesses a dense and stable structure that enables effective drug loading and sus-tained release.Its ability to prolong anti-inflammatory and analgesic effects has been validated in a mouse model of acute incisional pain.

Objective:To evaluate the immunogenicity of a quadrivalent influenza virus subunit vaccine in a healthy population aged 3-64 years.Methods:Healthy people aged 3-64 years old were selected as the study subjects, and a randomized, blind, positive controlled, non-inferiority test was adopted. The subjects were randomly inoculated with one dose of the corresponding experimental vaccine or control vaccine in a ratio of 1∶1. Blood samples were collected from all subjects before and at 28 d after immunization, and hemagglutination inhibition (HI) test was used to measure the levels of antibodies against H1N1, H3N2, B/Victoria (BV) and B/Yamagata (BY) in serum. The geometric mean titers (GMT), geometric mean increase (GMI), positive conversion rates and protection rates of antibodies against the four types of viruses were analyzed.Results:A total of 2 157 subjects aged 3-64 years were included, including 1 074 in the experimental group and 1 083 in the control group. There were no significant differences in the GMT or protection rates of antibodies against H1N1, H3N2, BV or BY before immunization between the two groups ( P>0.05), and the two groups were balanced at baseline. After full immunization, the GMI of antibodies to H1N1, H3N2, BV and BY in the experimental group was 11.16, 17.77, 9.61 and 15.13, respectively; the positive conversion rates were 84.08% (903/1 074), 92.46% (993/1 074), 86.03% (924/1 074) and 91.71% (985/1 074), respectively; the protection rates were 96.74% (1 039/1 074), 97.58% (1 048/1 074), 88.08% (946/1 074) and 94.97% (1 020/1 074), respectively. In the experimental group, the GMT of each antibody increased by more than 2.5 times after immunization; the lower limit of the 95%CI of the positive conversion rate was higher than 40%, and the lower limit of the 95%CI of the protection rate was higher than 70%. The lower limit of the 95%CI of the difference in the positive conversion rate of each antibody between the experimental group and the control group was >-10%, and the lower limit of the 95%CI for GMT (experimental group)/GMT (control group) was over 2/3. Conclusions:The experimental vaccine had good immunogenicity and was non-inferior to the control vaccine in the population aged 3-64 years.